Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate the effect of 5 mg KHK2375 on
progression free survival (PFS) when administered orally at weekly intervals in combination
with exemestane in a placebo-controlled, double-blind comparative study in subjects with
advanced or recurrent hormone receptor-positive breast cancer. The secondary objectives are
to investigate the effect of on overall survival (OS) and the antitumor effect and to
evaluate the pharmacokinetics and safety.